Good adherence to various LDL-lowering diets will reduce LDL-C levels by Moderate-intensity statins can be expected to reduce LDL-C levels by another 30% to 49%, and high-intensity statins by 50% CLINICAL STATEMENTS AND GUIDELINES (Table 3, Section 3.2.). The addition of ezetimibe or bile acid sequestrants to statin therapy typically provides an additional 15% to 25% reduction in LDL-C. Much greater additive reductions occur by adding a PCSK9 inhibitor to statin plus ezetimibe. In clinical practice, lifestyle and statin therapy are commonly introduced together. The maximum percentage change will occur by 4 to 12 weeks after starting a statin or combined therapy. At this time, drug efficacy or initial adherence to therapy can be evaluated. Periodic remeasurements will make it possible to confirm adherence to therapy. Because recommended intensities of drug thera- pies will vary in adolescents, young adults, adults 40 to 75 years of age, those with severe hyper- cholesterolemia, and those receiving therapy for secondary prevention, the recommended LDL-C levels to achieve will also vary. 4.4.4. Primary Prevention in Other Age Groups 4.4.4.1. Older Adults Additional recommendations for adults >75 years of age are included in Section 4.1. (Secondary ASCVD Pre- vention) and Section 4.3. (Diabetes Mellitus in Adults). Recommendations for Older Adults Referenced studies that support recommendations are summarized in Online Data Supplements 18 and 19. 